The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in Biogen's stock price. The Equal-Weight rating suggests that the analyst views the stock as fairly valued at its current price, but the lowered price target indicates a revision of the stock's future valuation, which might be interpreted negatively by the market.